Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 2
2023 2
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women.
Chayachinda C, Watananirun K, Phatihattakorn C, Anuwutnavin S, Niyomnaitham S, Phongsamart W, Lapphra K, Wittawatmongkol O, Rungmaitree S, Jansarikit L, Boonnak K, Wongprompitak P, Senawong S, Upadhya A, Toh ZQ, Licciardi PV, Chokephaibulkit K. Chayachinda C, et al. Among authors: jansarikit l. Hum Vaccin Immunother. 2023 Aug 1;19(2):2228670. doi: 10.1080/21645515.2023.2228670. Epub 2023 Jul 13. Hum Vaccin Immunother. 2023. PMID: 37439770 Free PMC article. Clinical Trial.
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
Niyomnaitham S, Quan Toh Z, Wongprompitak P, Jansarikit L, Srisutthisamphan K, Sapsutthipas S, Jantraphakorn Y, Mingngamsup N, Licciardi PV, Chokephaibulkit K. Niyomnaitham S, et al. Among authors: jansarikit l. Hum Vaccin Immunother. 2022 Nov 30;18(6):2091865. doi: 10.1080/21645515.2022.2091865. Epub 2022 Jul 11. Hum Vaccin Immunother. 2022. PMID: 35816053 Free PMC article. Clinical Trial.
Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study.
Buaboonnam J, Rungmaitree S, Piyaphanee N, Charuvanij S, Pitisuttithum O, Copeland K, Pheerapanyawaranun C, Jansarikit L, Niyomnaitham S, Chokephaibulkit K. Buaboonnam J, et al. Among authors: jansarikit l. Hum Vaccin Immunother. 2024 Dec 31;20(1):2428011. doi: 10.1080/21645515.2024.2428011. Epub 2024 Nov 22. Hum Vaccin Immunother. 2024. PMID: 39575846 Free PMC article.
Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty.
Niyomnaitham S, Chokephaibulkit K, Pheerapanyawaranun C, Toh ZQ, Licciardi PV, Satayasanskul A, Jansarikit L, Assantachai P. Niyomnaitham S, et al. Among authors: jansarikit l. J Nutr Health Aging. 2024 Aug;28(8):100315. doi: 10.1016/j.jnha.2024.100315. Epub 2024 Jul 17. J Nutr Health Aging. 2024. PMID: 39025017 Free article. Clinical Trial.